Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 4 (2007), Issue 5 (May)

1. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality.
   J Clin Oncol, 25(13): 1765-71. [Abstract] [Full-text]
2. Retropubic versus perineal radical prostatectomy in early prostate cancer: eight-year experience.
   J Surg Oncol, 95(6): 513-8. [Abstract] [Full-text]
3. Conformal thermal therapy using planar ultrasound transducers and adaptive closed-loop MR temperature control: demonstration in gel phantoms and ex vivo tissues.
   Phys Med Biol, 52(10): 2905-19. [Abstract] [Full-text]
4. Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract.
   Clin Cancer Res, 13(9): 2784-94. [Abstract] [Full-text]
5. Collagen XXIII expression is associated with prostate cancer recurrence and distant metastases.
   Clin Cancer Res, 13(9): 2634-42. [Abstract] [Full-text]
6. Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer.
   Clin Cancer Res, 13(9): 2541-8. [Abstract] [Full-text]
7. Partial-volume correction in PET: validation of an iterative postreconstruction method with phantom and patient data.
   J Nucl Med, 48(5): 802-10. [Abstract] [Full-text]
8. Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate.
   Cancer, 109(10): 2011-5. [Abstract] [Full-text]
9. Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate.
   Cancer, 109(10): 2004-10. [Abstract] [Full-text]
10. Effect of Akt inhibition on scatter factor-regulated gene expression in DU-145 human prostate cancer cells.
    Oncogene, 26(20): 2925-38. [Abstract] [Full-text]
11. The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1.
    Oncogene, 26(20): 2822-32. [Abstract] [Full-text]
12. Alterations in the serum glycome due to metastatic prostate cancer.
    J Proteome Res, 6(5): 1822-32. [Abstract] [Full-text]
13. The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor.
    Cancer Res, 67(9): 4514-23. [Abstract] [Full-text]
14. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice.
    Cancer Res, 67(9): 4399-407. [Abstract] [Full-text]
15. ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo.
    Cancer Res, 67(9): 4364-72. [Abstract] [Full-text]
16. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium.
    Cancer Res, 67(9): 4244-53. [Abstract] [Full-text]
17. Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells.
    Cancer Res, 67(9): 4219-26. [Abstract] [Full-text]
18. Integration of somatic deletion analysis of prostate cancers and germline linkage analysis of prostate cancer families reveals two small consensus regions for prostate cancer genes at 8p.
    Cancer Res, 67(9): 4098-103. [Abstract] [Full-text]
19. A coregulatory role for the mediator complex in prostate cancer cell proliferation and gene expression.
    Cancer Res, 67(9): 4034-41. [Abstract] [Full-text]
20. CYP19 TCT tri-nucleotide Del/Del genotype is a susceptibility marker for prostate cancer in a Taiwanese population.
    Urology, 69(5): 996-1000. [Abstract] [Full-text]
21. Prognostic significance of thymidylate synthase expression in patients with prostate cancer undergoing radical prostatectomy.
    Urology, 69(5): 988-95. [Abstract] [Full-text]
22. Incomplete and inconsistent information provided to men making decisions for treatment of early-stage prostate cancer.
    Urology, 69(5): 941-5. [Abstract] [Full-text]
23. Percent positive biopsy cores as a prognostic factor for prostate cancer treated with external beam radiation.
    Urology, 69(5): 936-40. [Abstract] [Full-text]
24. Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy.
    Urology, 69(5): 931-5. [Abstract] [Full-text]
25. Extent of prostatic atrophy in needle biopsies and serum PSA levels: is there an association?
    Urology, 69(5): 927-30. [Abstract] [Full-text]
26. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database.
    Urology, 69(5): 921-6. [Abstract] [Full-text]
27. Study of prostate cancer pathologic features in Chinese populations.
    Urology, 69(5): 915-20. [Abstract] [Full-text]
28. Outbreak of Pseudomonas aeruginosa infections after transrectal ultrasound-guided prostate biopsy.
    Urology, 69(5): 912-4. [Abstract] [Full-text]
29. Impact of variations in bony pelvic dimensions on performing radical retropubic prostatectomy.
    Urology, 69(5): 907-11. [Abstract] [Full-text]
30. Optimal site and number of biopsy cores according to prostate volume prostate cancer detection in Korea.
    Urology, 69(5): 902-6. [Abstract] [Full-text]
31. Rectourethral fistula after combination radiotherapy for prostate cancer.
    Urology, 69(5): 898-901. [Abstract] [Full-text]
32. Proteomic analysis of proteins regulated by TRPS1 transcription factor in DU145 prostate cancer cells.
    Biochim Biophys Acta, 1774(5): 575-82. [Abstract] [Full-text]
33. Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-kappaB in human prostate cell lines Differential time-dependent responses in cancer progression.
    Mol Cell Endocrinol, 270(1): 8-16. [Abstract] [Full-text]
34. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process.
    BMC Cancer, 7: 64. [Abstract] [Full-text]
35. A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells.
    Nucleic Acids Res, 35(8): 2767-76. [Abstract] [Full-text]
36. An androgen-IL-6-Stat3 autocrine loop re-routes EGF signal in prostate cancer cells.
    Mol Cell Endocrinol, 270(1): 50-6. [Abstract] [Full-text]
37. Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation.
    J Biol Chem, 282(19): 14094-100. [Abstract] [Full-text]
38. Significant decrease in angiopoietin-1 and angiopoietin-2 after radical prostatectomy in prostate cancer patients.
    Cancer Lett, 251(2): 296-301. [Abstract] [Full-text]
39. Expression of Nkx3.1 enhances 17beta-estradiol anti-tumor action in PC3 human prostate cancer cells.
    Asian J Androl, 9(3): 353-60. [Abstract] [Full-text]
40. Relationship between XRCC1 polymorphisms and susceptibility to prostate cancer in men from Han, Southern China.
    Asian J Androl, 9(3): 331-8. [Abstract] [Full-text]
41. African-American men's perceptions about prostate cancer: implications for designing educational interventions.
    Soc Sci Med, 64(11): 2189-200. [Abstract] [Full-text]
42. Low Gleason score prostatic adenocarcinomas are no longer viable entities.
    Histopathology, 50(6): 683-90. [Abstract] [Full-text]
43. Automatic segmentation of pelvic structures from magnetic resonance images for prostate cancer radiotherapy.
    Int J Radiat Oncol Biol Phys, 68(2): 592-600. [Abstract] [Full-text]
44. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas.
    Gastroenterology, 132(6): 2208-25. [Abstract] [Full-text]
45. Hedgehog is involved in prostate basal cell hyperplasia formation and its progressing towards tumorigenesis.
    Biochem Biophys Res Commun, 357(4): 1084-9. [Abstract] [Full-text]
46. Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth.
    Int J Radiat Oncol Biol Phys, 68(2): 499-507. [Abstract] [Full-text]
47. Hidden barriers between knowledge and behavior: the North Carolina prostate cancer screening and treatment experience.
    Cancer, 109(8): 1599-606. [Abstract] [Full-text]
48. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer.
    Cancer, 109(8): 1493-8. [Abstract] [Full-text]
49. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019.
    Cancer, 109(8): 1506-12. [Abstract] [Full-text]
50. Sexual function after three-dimensional conformal radiotherapy for prostate cancer: results from a dose-escalation trial.
    Int J Radiat Oncol Biol Phys, 68(2): 479-84. [Abstract] [Full-text]
51. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Cancer, 109(8): 1689-95. [Abstract] [Full-text]
52. PLC gamma contributes to metastasis of in situ-occurring mammary and prostate tumors.
    Oncogene, 26(21): 3020-6. [Abstract] [Full-text]
53. Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway.
    Br J Cancer, 96(10): 1595-604. [Abstract] [Full-text]
54. Differential expression of galectins in normal, benign and malignant prostate epithelial cells: silencing of galectin-3 expression in prostate cancer by its promoter methylation.
    Biochem Biophys Res Commun, 358(1): 241-6. [Abstract] [Full-text]
55. Expression signatures that correlated with Gleason score and relapse in prostate cancer.
    Genomics, 89(6): 666-72. [Abstract] [Full-text]
56. In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer.
    Br J Cancer, 96(10): 1587-94. [Abstract] [Full-text]
57. Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine.
    Cancer Immunol Immunother, 56(8): 1275-83. [Abstract] [Full-text]
58. Critical role for Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formation.
    J Natl Cancer Inst, 99(10): 811-22. [Abstract] [Full-text]
59. Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873).
    J Natl Cancer Inst, 99(10): 765-76. [Abstract] [Full-text]
60. Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study.
    J Natl Cancer Inst, 99(10): 754-64. [Abstract] [Full-text]
61. Prostate and lymph node proton magnetic resonance (MR) spectroscopic imaging with external array coils at 3 T to detect recurrent prostate cancer after radiation therapy.
    Invest Radiol, 42(6): 420-7. [Abstract] [Full-text]
62. Diffusion tensor magnetic resonance imaging of prostate cancer.
    Invest Radiol, 42(6): 412-9. [Abstract] [Full-text]
63. Anthropometrics and prostate cancer risk.
    Am J Epidemiol, 165(11): 1271-9. [Abstract] [Full-text]
64. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.
    Cancer Res, 67(10): 5033-41. [Abstract] [Full-text]
65. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer.
    Cancer Res, 67(10): 4904-14. [Abstract] [Full-text]
66. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo.
    Cancer Res, 67(10): 4807-15. [Abstract] [Full-text]
67. DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells.
    Cancer Res, 67(10): 4630-7. [Abstract] [Full-text]
68. Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling.
    J Urol, 177(6): 2352-6. [Abstract] [Full-text]
69. Salvage prostatectomy with bladder neck closure, continent catheterizable stoma and bladder augmentation: feasibility and patient reported continence outcomes at 32 months.
    J Urol, 177(6): 2200-4; discussion 2204. [Abstract] [Full-text]
70. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer.
    J Urol, 177(6): 2151-6; discussion 2156. [Abstract] [Full-text]
71. Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.
    J Urol, 177(6): 2146-50. [Abstract] [Full-text]
72. A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.
    J Urol, 177(6): 2141-5; discussion 2145. [Abstract] [Full-text]
73. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.
    J Urol, 177(6): 2136-40; discussion 2140. [Abstract] [Full-text]
74. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    J Urol, 177(6): 2132-5; discussion 2135. [Abstract] [Full-text]
75. Prostate cancer.
    J Urol, 177(6): 2020-9. [Abstract] [Full-text]
76. On the importance of race, socioeconomic status and comorbidity when evaluating quality of life in men with prostate cancer.
    J Urol, 177(6): 1992-9. [Abstract] [Full-text]
77. Prostate specific antigen recurrence after definitive therapy.
    J Urol, 177(6): 1985-91. [Abstract] [Full-text]
78. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.
    J Clin Oncol, 25(15): 2035-41. [Abstract] [Full-text]
79. Regulation of human CYP27A1 by estrogens and androgens in HepG2 and prostate cells.
    Arch Biochem Biophys, 462(1): 13-20. [Abstract] [Full-text]
80. Does the inhibition of c-myc expression mediate the anti-tumor activity of PPAR's ligands in prostate cancer cell lines?
    Arch Biochem Biophys, 462(1): 1-12. [Abstract] [Full-text]
81. Significant prostate-specific antigen (PSA) response to low-dose ketoconazole in a patient with non-metastatic androgen-independent prostate cancer (AIPC) and a review of the literature.
    Am J Ther, 14(3): 310-3. [Abstract] [Full-text]
82. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
    Proc Natl Acad Sci U S A, 104(20): 8455-60. [Abstract] [Full-text]
83. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation.
    Proc Natl Acad Sci U S A, 104(20): 8438-43. [Abstract] [Full-text]
84. Epidermotropic metastatic prostate carcinoma presenting as an umbilical nodule-Sister Mary Joseph nodule.
    Am J Dermatopathol, 29(3): 290-2. [Abstract] [Full-text]
85. LHRH agonists in prostate cancer: frequency of treatment, serum testosterone measurement and castrate level: consensus opinion from a roundtable discussion.
    Curr Med Res Opin, 23(5): 1077-80. [Abstract] [Full-text]
86. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial.
    Int J Hyperthermia, 23(3): 315-23. [Abstract] [Full-text]
87. The effect of oxytocin on cell proliferation in the human prostate is modulated by gonadal steroids: implications for benign prostatic hyperplasia and carcinoma of the prostate.
    Prostate, 67(10): 1132-42. [Abstract] [Full-text]
88. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells.
    Prostate, 67(10): 1121-31. [Abstract] [Full-text]
89. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
    Prostate, 67(10): 1099-110. [Abstract] [Full-text]
90. Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia.
    Prostate, 67(10): 1091-8. [Abstract] [Full-text]
91. Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride.
    Prostate, 67(10): 1111-20. [Abstract] [Full-text]
92. Feasibility of constructing tissue microarrays from diagnostic prostate biopsies.
    Prostate, 67(10): 1011-8. [Abstract] [Full-text]
93. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.
    Prostate, 67(10): 1081-90. [Abstract] [Full-text]
94. Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFR-mediated Akt and ERK signal transduction.
    Prostate, 67(10): 1061-9. [Abstract] [Full-text]
95. Feasibility study of adjustment for contamination and non-compliance in a prostate cancer screening trial.
    Prostate, 67(10): 1053-60. [Abstract] [Full-text]
96. Cytochrome P450 2B6 is a growth-inhibitory and prognostic factor for prostate cancer.
    Prostate, 67(10): 1029-37. [Abstract] [Full-text]
97. Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression.
    Prostate, 67(10): 1038-52. [Abstract] [Full-text]
98. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer.
    Cancer, 109(11): 2239-47. [Abstract] [Full-text]
99. Ethnic variation in return to baseline values of patient-reported outcomes in older prostate cancer patients.
    Cancer, 109(11): 2229-38. [Abstract] [Full-text]
100. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
     J Pathol, 212(1): 91-101. [Abstract] [Full-text]
101. Education predicts quality of life among men with prostate cancer cared for in the Department of Veterans Affairs: a longitudinal quality of life analysis from CaPSURE.
     Cancer, 109(9): 1769-76. [Abstract] [Full-text]
102. Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey.
     Cancer, 109(9): 1877-86. [Abstract] [Full-text]
103. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice.
     Cancer, 109(9): 1777-83. [Abstract] [Full-text]
104. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
     Am J Surg Pathol, 31(6): 889-94. [Abstract] [Full-text]
105. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.
     Am J Surg Pathol, 31(6): 882-8. [Abstract] [Full-text]
106. Positive-block ratio in radical prostatectomy specimens is an independent predictor of prostate-specific antigen recurrence.
     Am J Surg Pathol, 31(6): 877-81. [Abstract] [Full-text]
107. Solitary fibrous tumor on needle biopsy and transurethral resection of the prostate: a clinicopathologic study of 13 cases.
     Am J Surg Pathol, 31(6): 870-6. [Abstract] [Full-text]
108. Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6.
     Mol Cell Biol, 27(12): 4444-53. [Abstract] [Full-text]
109. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794.
     J Clin Oncol, 25(16): 2225-9. [Abstract] [Full-text]
110. Prospective non-randomized evaluation of four mediators of the systemic response after extraperitoneal laparoscopic and open retropubic radical prostatectomy.
     BJU Int, 99(6): 1461-6. [Abstract] [Full-text]
111. Venous thromboembolism and cyproterone acetate in men with prostate cancer: a study using the General Practice Research Database.
     BJU Int, 99(6): 1398-403. [Abstract] [Full-text]
112. Long-term effects of a short course of neoadjuvant luteinizing hormone-releasing hormone analogue and radical radiotherapy on the hormonal profile in patients with localized prostate cancer.
     BJU Int, 99(6): 1380-2. [Abstract] [Full-text]
113. Health-insurance status is a determinant of the stage at presentation and of cancer control in European men treated with radical prostatectomy for clinically localized prostate cancer.
     BJU Int, 99(6): 1404-8. [Abstract] [Full-text]
114. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.
     BJU Int, 99(6): 1415-20. [Abstract] [Full-text]
115. Does the molecular staging in pelvic lymph nodes improve the detection of relevant prostate cancer metastases? An assessment after 6 years.
     BJU Int, 99(6): 1409-14. [Abstract] [Full-text]
116. 11C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer.
     BJU Int, 99(6): 1421-6. [Abstract] [Full-text]
117. Economic conditions and marriage quality of men with prostate cancer.
     BJU Int, 99(6): 1391-7. [Abstract] [Full-text]
118. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies.
     BJU Int, 99(6): 1427-31. [Abstract] [Full-text]
119. Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials.
     BJU Int, 99(6): 1383-9. [Abstract] [Full-text]
120. Immunotherapy with dendritic cells for prostate cancer.
     Int J Cancer, 121(3): 467-73. [Abstract] [Full-text]
121. Ras-MEK-ERK signaling cascade regulates androgen receptor element-inducible gene transcription and DNA synthesis in prostate cancer cells.
     Int J Cancer, 121(3): 520-7. [Abstract] [Full-text]
122. SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer.
     Int J Cancer, 121(3): 615-20. [Abstract] [Full-text]
123. Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4).
     Int J Cancer, 121(3): 595-605. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.